RNS Number : 4014N
OptiBiotix Health PLC
20 May 2020

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Launch of SlimBiome® containing gummies in the USA

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that the Company has entered into a non-exclusive license agreement for its SlimBiome® trademark with Evolution_18 ("Evolution_18") and related launch of fibre gummies containing OptiBiotix's SlimBiome® proprietary weight management technology.

Evolution_18 is a US-based company founded by Bobbi Brown who is known for turning a simple makeup line, Bobbi Brown Essentials, into a billion-dollar global brand with Estée Lauder Companies (https://www.nytimes.com/2018/03/31/style/bobbi-brown-just-bobbi.html). Turning her focus to wellness products, she became a certified health coach and launched her wellness brand, Evolution_18, which turned out to be another success story with the listing of its products at 1,500 Walmart stores as of April 2019 and an estimated 3,000 Walmart stores in September 2019 (https://foundr.com/money-talks-bobbi-brown).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: *"We are very pleased to announce this new commercial launch in the USA. The partnership with Evolution_18 allows us to collaborate with a brand that is distributed in more than 3,000 Walmart stores in the USA and also further increase awareness of the SlimBiome® brand. This agreement builds on the recently announced launch of SlimBiome® containing products in the UK with Holland & Barrett (RNS: 7 January 2020), a partnership with OptiPharm, whose Optislim is Australia's best selling weight management brand (RNS: 31 March 2020), as well the signature of a non-exclusive agreement with Smart For Life (RNS: 4 May 2020) which made SlimBiome® available to customers at Walmart in the USA and Costco in Canada in early May.*

"This agreement with Evolution_18 demonstrates our ability to negotiate deals with increasingly large partners around the world. As announced on 18 May 2020, this has led to a change in the nature of our discussions with prospective commercial partners as we no longer have to demonstrate the validity or commercial value of our science leading to more deals (70%) expected to deliver revenues in the first year of agreement compared to 2019 (35%)."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com

Stephen O'Hara, Chief Executive	*Contact via Walbrook below*
Cairn Financial Advisers LLP (NOMAD) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: 020 7213 0880
finnCap (Broker) Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking)	Tel: 020 7220 0500
goetzpartners securities Limited Ulrich Kinzel	Tel: 0203 859 7725
Walbrook PR Ltd Anna Dunphy	Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRSFMFMUESSELI